(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Posts no revenue in the six months ended March 31, unchanged from a year earlier. Pretax loss narrows to GBP242,529 from GBP337,622. Read More
(Alliance News) - Nuformix PLC on Monday celebrated multiple patent wins, after grants in both Europe and the US signalled further protections for its fibrosis and oncology technology. Read More
Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Announce intention to raise gross proceeds of GBP150,000 through a subscription for 75.0 million new shares at a price of 0.20 pence each. The shares will represent 9.2% of Nuformix's enlarged issued share capital. Company will use the subscription's net proceeds primarily to further advance its NXP002 programme for the inhaled treatment of idiopathic pulmonary fibrosis. Read More
Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses. Read More
(Alliance News) - Nuformix PLC on Monday said it has been issued with a patent in Japan for NXP002, its potential novel inhaled treatment for idiopathic pulmonary fibrosis. Read More
Nuformix PLC - London-based pharmaceutical development company targeting unmet medical needs in fibrosis and oncology - Says it will receive immediate and near-term milestone payments as part of an update to its NXP001 exclusive licensing agreement with Oxilio Ltd. Nuformix does not disclose any financial details on this. Under the revised agreement, says Oxilio will acquire ownership of Nuformix's NXP001 patent estate. Says it will receive the additional milestone payments while retaining further development milestones and royalties capped at GBP2 million per year. Read More
(Alliance News) - Nuformix PLC on Monday reported a narrowed annual loss as it made progress on optimising costs and furthering its lead asset, NXP002. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Nuformix PLC on Monday said it has raised GBP70,000 through a subscription for 35.0 million new shares at a price of 0.20 pence each. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - Nuformix PLC on Wednesday said that, despite having to wait longer than expected, human disease tissue has now been acquired for its NXP002 programme. Read More
(Alliance News) - Nuformix PLC on Tuesday reported a negligibly smaller half-year loss as it continued to work on treatments for cancer and fibrosis, a disease which scars tissues in the lungs. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
Nuformix PLC - London-based pharmaceutical firm targeting fibrosis and oncology - Says NXP002, a potential treatment for idiopathic pulmonary fibrosis, has successfully completed pre-clinical tolerability studies. "Tolerability has been demonstrated across a new range of doses, including higher doses than previously given," it explains. Work now commences to explore how the new doses studied can best optimise efficacy and the treatment's positive pharmacological profile. Read More